GREEN LIFESCIENCE CO., LTD.: debt-to-equity, ROE and more
KOSDAQ, Legal name GREEN LIFESCIENCE CO., LTD.
Latest figures are the FY2025 separate summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 43.3%
- Equity ratio
- 69.8%
- ROE
- 0.3%
- Op. margin
- 0.5%
- Rev. growth
- 62.3%
- Interest coverage
- n/a
Condition flags
- Operating profit for 2 straight years.
- Total equity is above paid-in capital. Not capital-impaired.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
No dividend data yet for this company.
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2021 separate | 27.8% | 78.2% | -5.6% | -18.3% | n/a |
| FY2022 separate | 18.6% | 84.3% | -6.7% | -10.8% | 44.1% |
| FY2023 separate | 21.9% | 82.0% | -45.5% | -20.8% | -38.7% |
| FY2024 separate | 25.8% | 79.5% | 4.4% | 1.5% | 11.1% |
| FY2025 separate | 43.3% | 69.8% | 0.3% | 0.5% | 62.3% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | ₩25.3B | ₩36.5B | ₩22.4B | ₩24.9B | ₩40.3B |
| Operating profit | -₩4.6B | -₩4.0B | -₩4.6B | ₩376.9M | ₩204.3M |
| Pre-tax income | -₩3.4B | -₩2.9B | -₩16.4B | ₩1.6B | ₩110.1M |
| Net income | -₩3.1B | -₩3.5B | -₩16.4B | ₩1.6B | ₩110.1M |
| Total assets | ₩72.0B | ₩62.4B | ₩43.8B | ₩45.0B | ₩54.9B |
| Total liabilities | ₩15.7B | ₩9.8B | ₩7.9B | ₩9.2B | ₩16.6B |
| Total equity | ₩56.3B | ₩52.6B | ₩36.0B | ₩35.7B | ₩38.3B |
| Paid-in capital | ₩7.5B | ₩7.5B | ₩10.0B | ₩10.0B | ₩10.0B |
| Debt/equity (source value) | 27.8% | 18.6% | 21.9% | 25.8% | 43.3% |
Company outline (FSC)
- Market
- KOSDAQ
- Fiscal year end
- Dec
- Founded
- 2005-04-01
- Listed
- 09/12/22
- Employees
- 65
- Auditor
- 삼정회계법인
- Audit opinion
- 적정의견
- Corporate reg. no.
- 2062110029823
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for 그린생명과학Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.